Marc R. Shepard, MD

Marc R. Shepard, MD, specializes in general internal medicine at MedStar Medical Group and MedStar Health Research Institute. In addition, he is the medical director and a staff physician at a nursing home in northeast Washington, DC.

His clinical experience includes nearly 30 years as a private practice physician. He also has served as an associate professor at George Washington University and as an executive officer for a physician-owned company providing managed-care services. His research experience includes serving as a principal investigator and as a co-investigator on more than 50 phase 1-4 clinical trials. These trials have investigated the safety of pharmaceutical therapies for various conditions, including diabetes, high cholesterol and cardiovascular disease. Dr. Shepard’s research has been published in Clinical Infectious Diseases and Diabetes, Obesity and Metabolism.

Dr. Shepard is a fellow of the American College of Physicians, and he is certified by the American Board of Internal Medicine. He previously served as a physician advisor for the Delmarva Foundation, a federal Medicare Peer-Review Organization.

Dr. Shepard earned his medical degree at Northwestern University Medical School, Chicago. He completed an internship and a residency in internal medicine and primary care at George Washington University Hospital.

Research Interests

Dr. Shepard’s research interests include

  • Internal medicine
  • Diabetes
  • Hypertension
  • Hyperlipidemia
  • Obesity
  • Vaccines
  • New pharmaceutical therapies.

Selected Research

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Patients

Dr. Shepard is currently collaborating in this phase 3 trial sponsored by Boehringer Ingelheim. This multicenter, randomized, double-blind cardiovascular safety study is intended to investigate the safety of BI 10773 treatment in patients with type 2 diabetes and high risk for cardiovascular outcomes.

Safety of Belviq (Lorcaserin) in High-Risk Diabetic Patients

Dr. Shepard is currently an investigator on this study of a medication to promote weight loss in obese and overweight patients in conjunction with a reduced-calorie diet and an increase in physical activity.

Safety of Insulin Degludec

Dr. Shepard is collaborating on an investigation of the safety of a new injectable insulin used to treat high blood sugar in diabetic patients.

View Dr. Shepard’s publications on PubMed.

  • Research Areas
  • Endocrine/Diabetes/Lipids
  • Primary Care/Pediatrics